Sandra W. Jacob-Cowan
Basel, BS 4056, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.
Journal: Journal of medicinal chemistry
Published: May 24, 2022
Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase".
Journal: Angewandte Chemie (International ed. in English)
Published: December 20, 2021
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Journal: Leukemia research
Published: July 16, 2020
Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.
Journal: British journal of cancer
Published: June 21, 2019
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Journal: Journal of medicinal chemistry
Published: August 24, 2018
Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: August 01, 2017
The impact of structural biology in medicine illustrated with four case studies.
Journal: Journal of molecular medicine (Berlin, Germany)
Published: February 17, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Journal: Nature
Published: February 09, 2016
Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: January 21, 2016
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.
Journal: ACS medicinal chemistry letters
Published: March 10, 2015
Ten things you should know about protein kinases: IUPHAR Review 14.
Journal: British journal of pharmacology
Published: October 05, 2014
Last Updated: 09/26/2026